144 related articles for article (PubMed ID: 24863682)
61. Combined taxane-based chemotherapy and intensity-modulated radiotherapy with simultaneous integrated boost for gastroesophageal junction adenocarcinoma.
Spatola C; Tocco A; Pagana A; Milazzotto R; Luigi R; Salamone V; Militello C; Migliore M; Foti PV; Cataldo AD; Acquaviva G; Privitera G
Future Oncol; 2018 Mar; 14(6s):47-51. PubMed ID: 29664354
[TBL] [Abstract][Full Text] [Related]
62. [A case of stage IV advanced esophageal cancer with a long term survival by radiation therapy combined with nedaplatin and 5-FU chemotherapy].
Morimoto J; Oohira M; Kubo N; Tanaka H; Dan N; Muguruma K; Yashiro M; Sawada T; Yamashita Y; Nishiguchi Y; Hirakawa K
Gan To Kagaku Ryoho; 2009 Nov; 36(12):2436-8. PubMed ID: 20037448
[TBL] [Abstract][Full Text] [Related]
63. Different recurrence pattern after neoadjuvant chemoradiotherapy compared to surgery alone in esophageal cancer patients.
Smit JK; Güler S; Beukema JC; Mul VE; Burgerhof JG; Hospers GA; Plukker JT
Ann Surg Oncol; 2013 Nov; 20(12):4008-15. PubMed ID: 23838922
[TBL] [Abstract][Full Text] [Related]
64. Cisplatin/5-Fluorouracil (5-FU) Versus Carboplatin/Paclitaxel Chemoradiotherapy as Definitive or Pre-Operative Treatment of Esophageal Cancer.
Steber C; Hughes RT; McTyre ER; Soike M; Farris M; Levine BJ; Pasche B; Levine E; Blackstock AW
Cureus; 2021 Jan; 13(1):e12574. PubMed ID: 33575139
[TBL] [Abstract][Full Text] [Related]
65. Pretreatment surgical lymph node staging predicts results of trimodality therapy in esophageal cancer.
Jiao X; Krasna MJ; Sonett J; Gamliel Z; Suntharalingam M; Doyle A; Greenwald B
Eur J Cardiothorac Surg; 2001 Jun; 19(6):880-6. PubMed ID: 11404146
[TBL] [Abstract][Full Text] [Related]
66. The benefit of taxane-based therapies over fluoropyrimidine plus platinum (FP) in the treatment of esophageal cancer: a meta-analysis of clinical studies.
Wang T; Yu J; Liu M; Chen Y; Zhu C; Lu L; Wang M; Min L; Liu X; Zhang X; Gubat JA; Chen Y
Drug Des Devel Ther; 2019; 13():539-553. PubMed ID: 30787595
[TBL] [Abstract][Full Text] [Related]
67. Disparities in survival after trimodality therapy for esophageal adenocarcinoma.
Eng OS; Nelson RA; Konstantinidis I; Chao J; Erhunmwunsee L; Raz DJ; Kim JY
Dis Esophagus; 2018 Sep; 31(9):. PubMed ID: 29534155
[TBL] [Abstract][Full Text] [Related]
68. Risk Analysis of Pneumonitis in Taxane Therapy After Chemoradiotherapy for Patients With Metastatic or Recurrent Esophageal Cancer.
Kishida Y; Tsushima T; Endo M; Hamauchi S; Todaka A; Yokota T; Machida N; Yamazaki K; Fukutomi A; Onozawa Y; Yasui H
Am J Clin Oncol; 2018 Jan; 41(1):41-45. PubMed ID: 26422718
[TBL] [Abstract][Full Text] [Related]
69. Impact of the radiotherapy combined with cisplatin plus paclitaxel chemotherapy on the immunologic functions in the patients with esophageal cancer.
Liu R; Zhang J; He C; Jiang Q; Liu J; Fan R
Pak J Pharm Sci; 2016 Jul; 29(4 Suppl):1387-90. PubMed ID: 27592476
[TBL] [Abstract][Full Text] [Related]
70. Perioperative therapy with FLOT4 significantly increases survival in patients with gastroesophageal and gastric cancer in a large real-world cohort.
Möhring C; Mańczak A; Timotheou A; Sadeghlar F; Zhou T; Mahn R; Monin MB; Toma M; Feldmann G; Brossart P; Köksal M; Sarria GR; Sommer N; Lingohr P; Jafari A; Kalff JC; Strassburg CP; Gonzalez-Carmona MA
Int J Cancer; 2023 Aug; 153(3):609-622. PubMed ID: 36919950
[TBL] [Abstract][Full Text] [Related]
71. Comparison of efficacy, safety, and costs between neoadjuvant hypofractionated radiotherapy and conventionally fractionated radiotherapy for esophageal carcinoma.
Lyu J; Liu T; Li T; Li F; Wang Q; Wang J; Han Y; Wang J; Zhang J; Peng L; Lang J
Cancer Med; 2019 Jul; 8(8):3710-3718. PubMed ID: 31119872
[TBL] [Abstract][Full Text] [Related]
72. Cancer of the gastroesophageal junction: Current therapy options.
Ilson DH
Curr Treat Options Oncol; 2006 Sep; 7(5):410-23. PubMed ID: 16904058
[TBL] [Abstract][Full Text] [Related]
73. Isolated leptomeningeal carcinomatosis (carcinomatous meningitis) after taxane-induced major remission in patients with advanced breast cancer.
Kosmas C; Malamos NA; Tsavaris NB; Stamataki M; Gregoriou A; Rokana S; Vartholomeou M; Antonopoulos MJ
Oncology; 2002; 63(1):6-15. PubMed ID: 12187065
[TBL] [Abstract][Full Text] [Related]
74. Comparative effectiveness of platinum-based chemotherapy versus taxane and other regimens for ovarian cancer.
Du XL; Parikh RC; Lairson DR; Giordano SH; Cen P
Med Oncol; 2013 Mar; 30(1):440. PubMed ID: 23307252
[TBL] [Abstract][Full Text] [Related]
75. A Canadian single institution real-world experience using the CROSS trial regimen in the treatment of oesophageal and gastroesophageal junction carcinoma.
Khalid S; Hopman WM; Virik K
Intern Med J; 2022 Sep; 52(9):1587-1595. PubMed ID: 34139041
[TBL] [Abstract][Full Text] [Related]
76. The use of trimodality therapy for the treatment of operable esophageal carcinoma in the veteran population: patient survival and outcome analysis.
Billingsley KG; Maynard C; Schwartz DL; Dominitz JA
Cancer; 2001 Sep; 92(5):1272-80. PubMed ID: 11571743
[TBL] [Abstract][Full Text] [Related]
77. The role of definitive chemoradiation in patients with non-metastatic oesophageal cancer.
Jeene PM; van Laarhoven HWM; Hulshof MCCM
Best Pract Res Clin Gastroenterol; 2018; 36-37():53-59. PubMed ID: 30551857
[TBL] [Abstract][Full Text] [Related]
78. Mixed adenoneuroendocrine carcinoma (MANEC) of the gastroesophageal junction: a case report and review of the literature.
Juanmartiñena JF; Fernández-Urién I; Córdoba A; Miranda C; Borda A
Rev Esp Enferm Dig; 2017 Feb; 109(2):160-162. PubMed ID: 26999428
[TBL] [Abstract][Full Text] [Related]
79. Improvement in survival for patients with synchronous metastatic esophageal cancer in the south of the Netherlands from 1994 to 2013.
Bernards N; Haj Mohammad N; Creemers GJ; Rozema T; Roukema JA; Nieuwenhuijzen GA; van Laarhoven HW; van der Sangen M; Lemmens VE
Acta Oncol; 2016; 55(9-10):1161-1167. PubMed ID: 27174793
[TBL] [Abstract][Full Text] [Related]
80. Tumor Platinum Concentrations and Pathological Responses Following Cisplatin-Containing Chemotherapy in Gastric Cancer Patients.
Cao Y; Chang Q; Cabanero M; Zhang W; Hafezi-Bakhtiari S; Hedley D; Darling G; Quereshy F; Jang R; Elimova E; Knox J; Ornatsky O; Serra S; Chen E
J Gastrointest Cancer; 2019 Dec; 50(4):801-807. PubMed ID: 30117091
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
